Harvard Catalyst Profiles

Contact, publication, and social network information about Harvard faculty and fellows.

Howard David Sesso, Sc.D.

Co-Author

This page shows the publications co-authored by Howard Sesso and Kathryn Penney.
Connection Strength

1.441
  1. Association of Prostate Cancer Risk Variants with TMPRSS2:ERG Status: Evidence for Distinct Molecular Subtypes. Cancer Epidemiol Biomarkers Prev. 2016 05; 25(5):745-9.
    View in: PubMed
    Score: 0.163
  2. Replication of a genetic variant for prostate cancer-specific mortality. Prostate Cancer Prostatic Dis. 2015 Sep; 18(3):260-3.
    View in: PubMed
    Score: 0.154
  3. Association of prostate cancer risk variants with gene expression in normal and tumor tissue. Cancer Epidemiol Biomarkers Prev. 2015 Jan; 24(1):255-60.
    View in: PubMed
    Score: 0.149
  4. Plasma antioxidants, genetic variation in SOD2, CAT, GPX1, GPX4, and prostate cancer survival. Cancer Epidemiol Biomarkers Prev. 2014 Jun; 23(6):1037-46.
    View in: PubMed
    Score: 0.143
  5. Gleason grade progression is uncommon. Cancer Res. 2013 Aug 15; 73(16):5163-8.
    View in: PubMed
    Score: 0.137
  6. Selenoprotein P genetic variants and mrna expression, circulating selenium, and prostate cancer risk and survival. Prostate. 2013 May; 73(7):700-5.
    View in: PubMed
    Score: 0.130
  7. mRNA expression signature of Gleason grade predicts lethal prostate cancer. J Clin Oncol. 2011 Jun 10; 29(17):2391-6.
    View in: PubMed
    Score: 0.117
  8. Association of KLK3 (PSA) genetic variants with prostate cancer risk and PSA levels. Carcinogenesis. 2011 Jun; 32(6):853-9.
    View in: PubMed
    Score: 0.116
  9. Cholesterol Metabolism and Prostate Cancer Lethality. Cancer Res. 2016 08 15; 76(16):4785-90.
    View in: PubMed
    Score: 0.042
  10. Molecular differences in transition zone and peripheral zone prostate tumors. Carcinogenesis. 2015 Jun; 36(6):632-8.
    View in: PubMed
    Score: 0.038
  11. Genetic variation across C-reactive protein and risk of prostate cancer. Prostate. 2014 Jul; 74(10):1034-42.
    View in: PubMed
    Score: 0.036
  12. SPINK1 protein expression and prostate cancer progression. Clin Cancer Res. 2014 Sep 15; 20(18):4904-11.
    View in: PubMed
    Score: 0.036
  13. Modification of the association between obesity and lethal prostate cancer by TMPRSS2:ERG. J Natl Cancer Inst. 2013 Dec 18; 105(24):1881-90.
    View in: PubMed
    Score: 0.035
  14. The TMPRSS2:ERG rearrangement, ERG expression, and prostate cancer outcomes: a cohort study and meta-analysis. Cancer Epidemiol Biomarkers Prev. 2012 Sep; 21(9):1497-509.
    View in: PubMed
    Score: 0.032
  15. Common polymorphisms in the adiponectin and its receptor genes, adiponectin levels and the risk of prostate cancer. Cancer Epidemiol Biomarkers Prev. 2011 Dec; 20(12):2618-27.
    View in: PubMed
    Score: 0.030
  16. Genetic variation in the toll-like receptor 4 and prostate cancer incidence and mortality. Prostate. 2012 Feb 01; 72(2):209-16.
    View in: PubMed
    Score: 0.029
  17. Genetic variation in RNASEL associated with prostate cancer risk and progression. Carcinogenesis. 2010 Sep; 31(9):1597-603.
    View in: PubMed
    Score: 0.028
  18. Immunohistochemical expression of BRCA1 and lethal prostate cancer. Cancer Res. 2010 Apr 15; 70(8):3136-9.
    View in: PubMed
    Score: 0.027
Connection Strength
The connection strength for co-authors is the sum of the scores for each of their shared publications.

Publication scores are based on many factors, including how long ago they were written and whether the person is a first or senior author.
Funded by the NIH National Center for Advancing Translational Sciences through its Clinical and Translational Science Awards Program, grant number UL1TR002541.